Member Info for Laura2022

Tomorrow should open up

Yoda

Very kind

Can buy AND sell at 0.1p

Bought more

Added another 50k shares

Can buy £10k buy not £11k

Suggests that's about how much left

Tempting

The 50k looks like SB

Stark

22mln

Afternoon all

Is this totally binary .....death or glory

Csn anyone give a reasoned summary plz

Arthur

Too true

I have nearly 10 filtered on IMM alone

Bid now up again

0.985p for 20mln

Jimmy

Yes, also can sell 20mln at 0.98

Bobat

Not me, but im up to 20mln now

Life is good

Just report to

Info@lse.co.uk

He (Avocet123) has spent 5yrs trolling

First equity

MPL 500% profits used :)

So I see it as a "free" opportunity

Best wishes

Currently ticked up on bid

Currently 0.98 to 0.1p for 10mln

Lets see what happens over next few weeks

The Company selectively deploys capital across lending, market-neutral strategies, liquidity provision, and structured products. Indicative yields achieved to date include approximately 4% on physical gold lending and approximately 20% on Tether Gold structured products.

 

Integrated Model

 

BMV's approach combines:

· Origination of asset-backed cash flows

· Capture of proceeds within treasury

· Redeployment into yield strategies

· Recycling of capital into new opportunities

 

This creates a repeatable model designed to enhance returns through continuous capital reuse.

 

Legacy Assets

 

The Company continues to undertake a strategic review of its legacy portfolio, comprising historical interests in gold mining assets in Asia. Based on work completed to date, the Board does not currently expect these assets to be monetised in the medium to long term and is therefore exploring potential disposal options. No decisions have been finalised, and further updates will be provided as appropriate.

 

Sath Ganesarajah, Chief Executive Officer of BMV, said: "We have made strong progress across our pipeline as we execute our gold streaming and treasury strategy. BMV is in advanced discussions on a number of potential transactions that meet our criteria of short-duration paybacks and attractive returns. Our focus remains on closing these pipeline opportunities, scaling our treasury deployment, and integrating both into a unified capital framework. Our objective is to build a scalable platform capable of compounding capital through a combination of asset ownership and active treasury management. We look forward to updating the market as these opportunities progress."

 

Taken from elsewhere so DYOR snd NAI

Lupuzor prediction: Sales $5 billion pa, 30% royalty to Immupharma + $150 million pa licensing fee to Immupharma; gives $1.5 billion + $150 m = $1.65 billion pa revenues to Immupharma. 96%+ gross margin, say $1.25 billion pa net (after tax, etc), on PE ratio of 20 = $25 billion market capitalisation for Immupharma = Approx Immupharma share price £140.

Cavalier

Just filter like I did last year

Meanwhile

Very tight 8.72p to 8.79p

P140 partnering discussions

As reiterated in recent announcements, P140 remains a core value driver for ImmuPharma. The Company continues to progress discussions with a number of potential partners, including under signed confidentiality agreements. The management team also attended the Bio-Europe Spring healthcare event in Lisbon this week, where a number of meetings were held in relation to P140. ImmuPharma remains focused on completing a value‑enhancing licensing deal in 2026.